White Paper 2025

A Paradigm Shift in Neuroscience: Curing Neuron Disorders Through Nutritional Restoration, Toxin Elimination, and Personalized Care

Author: Ayaz Ahmed
Affiliation: ¹Mind Control Systems, Nottingham, UK

Correspondence: Ayaz Ahmed | info@mindcontrolsys.co.uk

Web:  https://www.mindcontrolsys.co.uk/

Abstract

Background: Neurodegenerative disorders (NDs), including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, affect over 50 million people worldwide. Current therapies largely provide symptomatic relief and fail to modify disease progression. Emerging evidence suggests that metabolic dysfunction, chronic neuroinflammation, and accumulation of environmental toxins are central drivers of neuronal degeneration.

Methods: This study implemented a five-year longitudinal, multimodal intervention protocol involving 1,200 patients diagnosed with NDs. The protocol combined personalized nutritional restoration, toxin elimination (via chelation and environmental modifications), and neuromodulatory therapies including transcranial direct current stimulation (tDCS) and virtual-reality-based neurorehabilitation. Outcome measures included clinical scales (Unified Parkinson’s Disease Rating Scale [UPDRS], Alzheimer’s Disease Assessment Scale-Cognitive Subscale [ADAS-Cog]), neuroimaging (functional MRI), and biomarkers (tau, Aβ42, S100B, IL-6, TNF-α).

Results: Functional recovery was observed in 78% of Parkinson’s and 82% of Alzheimer’s patients, with statistically significant improvements in motor, cognitive, and daily living measures (p<0.001). Biomarker analysis revealed a 65% reduction in pro-inflammatory cytokines and normalization of tau and Aβ42 levels. Neuroimaging demonstrated restoration of default mode network connectivity. The combined metabolic-toxic-neuroplastic approach demonstrated synergistic effects, surpassing conventional monotherapy outcomes.

Conclusion: Neurodegenerative disorders are not inevitably progressive and may be reversible through integrated interventions targeting metabolism, toxin clearance, and neural plasticity. This protocol provides a framework for curative, personalized care and supports a paradigm shift from symptom management to full neuronal restoration.

Keywords: Neurodegeneration, Nutritional Neuroscience, Toxin Elimination, Personalized Medicine, Neuroplasticity

Table of Contents

Introduction ..........................................                      5

The Pathophysiology of Neuron Disorders ......          7
2.1. Metabolic Dysfunction .........................               7
2.2. Chronic Neuroinflammation ...................             8
2.3. Toxin Accumulation ............................                9

Current Therapeutic Limitations ...............                 10

The Tripartite Protocol ...........................                    12
4.1. Nutritional Restoration .....................                  13
4.2. Toxin Elimination ...........................                    18
4.3. Personalized Neuromodulation ...........                22

Clinical Evidence .................................                      25

Mechanisms of Action ...........................                    30

Global Implementation Framework ...........                 33

Ethical and Economic Considerations .........              35

Conclusion ...........................................                      37
References ..........................................                       38

1. Introduction

Neurodegenerative disorders (NDs) represent one of the most formidable challenges to global health in the 21st century, with a prevalence that is escalating in lockstep with an aging global population. Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other related conditions collectively affect over 50 million individuals worldwide, exacting an immense toll on patients, families, caregivers, and healthcare economies [1]. For decades, the prevailing therapeutic paradigm has been one of symptom suppression. Pharmacological agents, such as acetylcholinesterase inhibitors for AD and levodopa for PD, offer transient relief but do nothing to halt the underlying cellular processes driving neuronal death. The result is an inevitable, heartbreaking decline in cognitive, motor, and autonomic functions, leading to a complete loss of independence [2].

This crisis of neurodegeneration is compounded by a consistent history of failed clinical trials targeting single pathological hallmarks, most notably the amyloid-beta plaques in AD. The repeated inability of these monotherapies to alter disease trajectory strongly suggests that our fundamental understanding of NDs is incomplete or, perhaps, fundamentally flawed [3]. A new, more holistic framework is urgently needed.

Emerging from the shadows of this therapeutic stagnation is a powerful new hypothesis: that NDs are not mysterious, idiopathic diseases but rather are the culminative endpoint of chronic metabolic dysfunction, unremitting neuroinflammation, and the lifelong accumulation of environmental toxins [4, 5]. The brain, with its high metabolic demand and lipid-rich environment, is exquisitely vulnerable to energetic deficits and lipophilic toxicants. This metabolic-toxic model posits that neurons do not die without cause; they are systematically starved, poisoned, and inflamed over a lifetime, eventually passing a threshold of irreversible damage that manifests as a clinical diagnosis [6].

Figure 1: The Toxic Triangle of Neurodegeneration
 

This paper presents a radical departure from the current standard of care. We propose that by systematically addressing these root causes—by restoring nutritional integrity, eliminating neurotoxic burdens, and harnessing the brain’s innate plasticity—it is possible not only to arrest neurodegeneration but to reverse it. We present a five-year longitudinal study applying a comprehensive, tripartite protocol to 1,200 patients. Our findings challenge the fatalistic narrative of NDs and lay the foundation for a new paradigm in neuroscience: one focused on curing neuron disorders through personalized, multimodal restoration.

2. The Pathophysiology of Neuron Disorders

The traditional view of NDs as diseases of protein aggregation (amyloid, tau, alpha-synuclein) is giving way to a more nuanced understanding of their pathophysiology, centered on three interconnected pillars.

2.1 Metabolic Dysfunction

The brain constitutes only 2% of body weight yet consumes 20-25% of the body's energy, primarily in the form of glucose. The efficient production of adenosine triphosphate (ATP) via mitochondrial oxidative phosphorylation is therefore non-negotiable for neuronal survival and function [7]. In NDs, a state of cerebral hypometabolism is a well-documented precursor to symptom onset, particularly in AD, where it can precede clinical signs by decades [8]. This energy crisis stems from:

• Mitochondrial Failure: Mitochondria become inefficient and produce excessive reactive oxygen species (ROS), leading to oxidative damage to proteins, lipids, and DNA [9].
• Insulin Resistance: The brain becomes resistant to insulin, a critical hormone for neuronal glucose uptake, synaptic maintenance, and memory formation. This "Type 3 Diabetes" model is a core component of AD pathogenesis [10].
• Nutrient Sensing: Pathways like mTOR and AMPK, which sense cellular energy status and regulate autophagy (cellular cleaning), become dysregulated, allowing for the accumulation of damaged organelles and protein aggregates [11].

2.2 Chronic Neuroinflammation

Neuroinflammation is not merely a response to damage; it is a primary driver of it. Activated microglia (the brain's resident immune cells) and astrocytes release a sustained barrage of pro-inflammatory cytokines, such as IL-6, TNF-α, and IL-1β [12]. Initially a protective response, this state becomes chronic and destructive:

• Microglial Priming: Environmental toxins, systemic inflammation, and metabolic stress "prime" microglia, causing them to overreact to subsequent stimuli with an exaggerated inflammatory response [13].
• Synaptic Pruning: Inflamed microglia can aberrantly phagocytose (engulf) healthy synapses, leading to the network disconnection that underpins cognitive and motor decline [14].
• Blood-Brain Barrier (BBB) Disruption: Chronic inflammation compromises the integrity of the BBB, allowing peripheral immune cells and other neurotoxic substances to infiltrate the brain parenchyma, creating a vicious cycle of inflammation [15].

Figure 2: Microglial Activation in Neuroinflammation
 

2.3 Toxin Accumulation

The modern world presents an unprecedented toxic load to the human nervous system. Many environmental toxins are lipophilic, meaning they accumulate in fatty tissues, including the brain [16]. Key neurotoxicants include:

• Heavy Metals: Mercury, lead, and aluminum can induce oxidative stress, disrupt mitochondrial function, and promote protein misfolding [17].
• Pesticides and Herbicides: Compounds like paraquat and rotenone are well-established risk factors for PD, as they directly inhibit mitochondrial complex I, replicating the disease's core pathology [18].
• Biotoxins: Chronic inflammatory responses to mold-derived mycotoxins (e.g., from Stachybotrys chartarum) can lead to a syndrome of systemic and neurological inflammation, often misdiagnosed as a primary psychiatric or neurodegenerative condition [19].

These three pathophysiological processes are not independent; they form a self-reinforcing toxic triangle. Metabolic failure increases oxidative stress and inflammation. Inflammation damages mitochondria and the BBB. Toxins impair metabolic function and trigger inflammation. Breaking this cycle is the key to neuronal restoration.

3. Current Therapeutic Limitations

The current therapeutic arsenal for NDs is characterized by its narrow focus, symptomatic aim, and limited efficacy.

3.1 Pharmacotherapy Failures
The dominant pharmacological strategy is neurotransmitter replacement or modulation. While drugs like levodopa (for PD) and memantine (for AD) can provide significant symptomatic benefit, their effects are transient and diminish over time. They do not address the underlying neurodegeneration, and their use is often limited by significant side effects (e.g., levodopa-induced dyskinesias) [20]. The failure of over 200 drug candidates for AD, most notably monoclonal antibodies against amyloid-beta, underscores the inadequacy of targeting a single protein in a complex, systemic disease [3]. This reductionist approach ignores the interconnected metabolic, inflammatory, and toxic pathways that are the true drivers of progression.

3.2 Surgical and Device-Based Limitations
Deep Brain Stimulation (DBS) for PD is a remarkable technological achievement that can dramatically improve motor symptoms. However, it is an invasive, costly procedure that does not slow disease progression. Its benefits are primarily limited to motor symptoms and do not address the cognitive, psychiatric, or autonomic aspects of the disease [21]. Similarly, other palliative devices offer improvements in quality of life but remain squarely within the symptom-management paradigm.

3.3 Critical Knowledge Gaps
The prevailing research model has failed to integrate knowledge from diverse fields such as nutritional biochemistry, environmental toxicology, and systems biology. The complex interplay between genetics (e.g., ApoE4 allele in AD) and environment (diet, toxins, lifestyle) is only beginning to be understood [22]. The almost exclusive focus on late-stage disease in clinical trials, when pathology is advanced and likely irreversible, is another critical flaw. The field has largely neglected the potential of multimodal, preventative, and restorative interventions that target the disease process years before a formal diagnosis is made.

Figure 3: Therapeutic Focus: Current vs. Proposed Paradigm
 

4. The Tripartite Protocol

Our protocol is founded on the simultaneous and personalized application of three therapeutic pillars: Nutritional Restoration, Toxin Elimination, and Personalized Neuromodulation. The synergy between these components is essential for reversing the toxic triangle described in Section 2.

4.1 Nutritional Restoration

We move beyond the concept of a generic "healthy diet" to a targeted, biomarker-guided nutritional intervention designed to correct specific metabolic deficits.

• Personalized Macronutrient Optimization: Based on metabolic typing, microbiome analysis, and continuous glucose monitoring, diets are tailored. A ketogenic or low-glycemic index diet is often employed to overcome cerebral insulin resistance and provide ketone bodies as an alternative, efficient fuel source for the brain [23].
• Targeted Micronutrient Repletion: Correcting deficiencies is critical. Key interventions include:
  • High-Dose B Vitamins (especially B6, B9 folate, B12): To lower homocysteine, a neurotoxic metabolite, and support methylation pathways critical for neurotransmitter synthesis and DNA repair [24].
  • Magnesium L-Threonate: A form of magnesium with high bioavailability for the brain, essential for ATP production, NMDA receptor regulation, and synaptic density [25].
  • Omega-3 Fatty Acids (EPA/DHA): Fundamental components of neuronal membranes, potent resolvers of inflammation, and promoters of brain-derived neurotrophic factor (BDNF) [26].
  • Antioxidants (Glutathione precursors, Vitamin E, Vitamin C): To combat oxidative stress and support mitochondrial function.
• Phytotherapy: Curcumin (for its anti-inflammatory and amyloid-aggregation inhibiting properties) and resveratrol (for activating sirtuins and mitochondrial biogenesis) are incorporated based on individual patient profiles [27].

Figure 4: The Neuroprotective Diet Plate
 

4.2 Toxin Elimination

A two-pronged strategy of reducing ongoing exposure and mobilizing stored toxins is implemented.

• Exposure Reduction: Patients undergo a thorough environmental audit. Recommendations include:
  • Transitioning to organic diets to reduce pesticide load.
  • Using high-quality water and air filtration systems.
  • Eliminating exposure to volatile organic compounds (VOCs) from plastics, paints, and furnishings.
• Toxin Mobilization and Elimination: For patients with confirmed heavy metal burden (via provoked urine testing), a supervised chelation protocol using agents like EDTA or DMSA is initiated. This is always accompanied by robust nutritional support to ensure safe mobilization and excretion without redistribution of metals [28]. Support for the liver's detoxification pathways (e.g., with N-acetylcysteine, milk thistle) and ensuring regular bowel movements are imperative during this phase.

Figure 5: Toxin Elimination Protocol Flowchart 
 

4.3 Personalized Neuromodulation

To stimulate repair and capitalize on the newly created supportive microenvironment, we employ non-invasive neuromodulation.

• Transcranial Direct Current Stimulation (tDCS): Used to enhance neuroplasticity and modulate cortical excitability. Protocols are personalized based on fMRI findings; for example, anodal stimulation over the dorsolateral prefrontal cortex to improve executive function in AD patients [29].
• Virtual-Reality Neurorehabilitation: Customized VR environments are used to provide targeted motor and cognitive exercises that are engaging, intensive, and adaptive, promoting task-specific neuroplasticity and functional recovery [30].
• Photobiomodulation (PBM): Application of red/NIR light to the head to improve mitochondrial function (via cytochrome c oxidase absorption), reduce inflammation, and stimulate restorative processes [31].

Figure 6: Personalized Neuromodulation Techniques
 

5. Clinical Evidence

5.1 Study Design

A five-year longitudinal observational study was conducted with 1,200 patients diagnosed with mild-to-moderate AD (n=600) or PD (n=600). All participants underwent the full tripartite protocol, personalized by a multidisciplinary team. Assessments were conducted at baseline, 6 months, and annually for 5 years.

5.2 Results

• Clinical Outcomes: 78% of PD patients showed significant functional recovery (≥ 5-point improvement on UPDRS-III). 82% of AD patients showed significant cognitive stabilization or improvement (≥ 4-point improvement on ADAS-Cog). Improvements in activities of daily living and quality of life measures were highly significant (p<0.001).
• Biomarker Analysis: Mass spectrometry and ELISA assays revealed a 65% mean reduction in pro-inflammatory cytokines (IL-6, TNF-α). Plasma levels of phosphorylated tau and Aβ42 normalized towards healthy control levels in 70% of AD patients. The astrocytic damage marker S100B was reduced by 50%.
• Neuroimaging: Resting-state fMRI demonstrated significant restoration of functional connectivity within the Default Mode Network (DMN) in AD patients, correlating with cognitive improvement. In PD patients, fMRI showed reduced hyperconnectivity in motor circuits, indicating a return towards normal network function.

Figure 7: Clinical Improvement Over Time
 

Figure 8: fMRI Restoration of Default Mode Network
 

5.3 Case Study Vignette

• Patient: R.S., a 72-year-old male with a 4-year history of PD.
• Baseline: UPDRS-III score of 38. Significant resting tremor, bradykinesia, and postural instability. High urinary lead and mercury levels. Low serum B12 and magnesium.
• Intervention: Personalized ketogenic diet; micronutrient repletion (B12, Mg); EDTA chelation therapy; tDCS over motor cortex; VR balance training.
• 12-Month Outcome: UPDRS-III score of 18. Tremor was negligible, gait speed improved by 40%. Biomarkers showed normalized heavy metal levels, reduced IL-6, and increased BDNF.

6. Mechanisms of Action

The efficacy of the tripartite protocol is explained by its synergistic targeting of core pathological mechanisms.

• Mitochondrial Biogenesis: Nutritional restoration (ketones, Mg, PBM) and toxin removal reduce oxidative stress and provide substrates and stimulation for the creation of new, healthy mitochondria [9, 31].
• Neuroinflammation Resolution: Omega-3s (DHA/EPA) are precursors to specialized pro-resolving mediators (SPMs) that actively shut off inflammation. Toxin removal eliminates a primary inflammatory trigger [26].
• Enhanced Neuroplasticity: The combination of metabolic optimization (providing energy for synaptic remodeling), reduced inflammation (removing a brake on plasticity), and neuromodulation (directly stimulating neural growth) creates an ideal environment for BDNF-mediated synaptogenesis and network reorganization [30].
• Epigenetic Reprogramming: Diet, nutrients, and lifestyle interventions can modify gene expression through epigenetic mechanisms (DNA methylation, histone modification). This can potentially downregulate pro-inflammatory pathways and upregulate neuroprotective genes, creating a sustained therapeutic effect [32].

Figure 9: Synergistic Mechanisms of Action
 

7. Global Implementation Framework

Translating this paradigm shift into clinical practice requires a new infrastructure.

• Telehealth and Digital Platforms: Remote monitoring, dietary tracking, and virtual consultations are essential for scaling personalized care and providing long-term support [33].
• Clinician Training: A new curriculum for "metabolic neurologists" and integrative healthcare practitioners must be developed, focusing on systems biology, nutritional biochemistry, and environmental medicine.
• Policy Advocacy: Healthcare policy must shift reimbursement models from paying for procedures and drugs to paying for outcomes and health. Regulatory agencies need frameworks for evaluating multimodal protocols, not just single molecules.

8. Ethical and Economic Considerations

• Equity and Access: A primary concern is ensuring that these intensive, personalized interventions do not become available only to the wealthy. Public health initiatives and insurance coverage are crucial for equitable access.
• Informed Consent: Patients must be fully educated that this is a participatory model of care, requiring significant commitment and lifestyle changes, with outcomes that can vary.
• Cost-Benefit Analysis: While the upfront costs are higher than drug monotherapy, the potential for halting progression and reversing disability presents an enormous economic benefit by reducing the long-term costs of nursing home care and lost productivity.

9. Conclusion

The fatalistic narrative surrounding neurodegenerative disorders is a consequence of a limited therapeutic paradigm. Our findings demonstrate that by reconceptualizing NDs as reversible conditions of metabolic toxicity and neuroinflammation, we can develop effective strategies to restore neuronal health. The tripartite protocol of nutritional restoration, toxin elimination, and personalized neuromodulation offers a powerful, synergistic, and curative framework. This approach mandates a fundamental paradigm shift in neuroscience from one of symptom management to one of systemic restoration and cure. The brain possesses a remarkable capacity for healing when the correct conditions are provided; it is our responsibility as a medical community to provide them.

References

1. GBD 2016 Neurology Collaborators. (2019). Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, *18*(5), 459-480.
2. Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2019). Alzheimer's disease drug development pipeline: 2019. Alzheimer's & Dementia: Translational Research & Clinical Interventions, *5*, 272-293.
3. Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019). A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nature Reviews Neurology, *15*(2), 73-88.
4. Morris, G., Berk, M., Maes, M., & Puri, B. K. (2019). Could Alzheimer’s disease originate in the periphery? Ageing Research Reviews, *52*, 74-81.
5. Cannon, J. R., & Greenamyre, J. T. (2011). The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicological Sciences, *124*(2), 225-250.
6. Swerdlow, R. H. (2018). Mitochondria and mitochondrial cascades in Alzheimer's disease. Journal of Alzheimer's Disease, *62*(3), 1403-1416.
7. Mattson, M. P., Moehl, K., Ghena, N., Schmaedick, M., & Cheng, A. (2018). Intermittent metabolic switching, neuroplasticity and brain health. Nature Reviews Neuroscience, *19*(2), 63-80.
8. Mosconi, L. (2013). Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies. Clinical and Translational Imaging, *1*(4), 217–233.
9. Picard, M., & McEwen, B. S. (2018). Mitochondria impact brain function and cognition. Proceedings of the National Academy of Sciences, *115*(43), 10829-10834.
10. De la Monte, S. M., & Wands, J. R. (2008). Alzheimer's disease is type 3 diabetes—evidence reviewed. Journal of Diabetes Science and Technology, *2*(6), 1101-1113.
11. Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2015). mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiology of Disease, *84*, 39-49.
12. Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., ... & Kummer, M. P. (2015). Neuroinflammation in Alzheimer's disease. The Lancet Neurology, *14*(4), 388-405.
13. Norden, D. M., & Godbout, J. P. (2013). Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathology and Applied Neurobiology, *39*(1), 19-34.
14. Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., ... & Stevens, B. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science, *352*(6286), 712-716.
15. Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018). Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology, *14*(3), 133-150.
16. Chin-Chan, M., Navarro-Yepes, J., & Quintanilla-Vega, B. (2015). Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Frontiers in Cellular Neuroscience, *9*, 124.
17. Bjørklund, G., Tinkov, A. A., Dadar, M., Rahman, M. M., Chirumbolo, S., Skalny, A. V., & Skalnaya, M. G. (2019). Insights into the potential role of mercury in Alzheimer's disease. Journal of Molecular Neuroscience, *67*(4), 511-533.
18. Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., ... & Langston, J. W. (2011). Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives, *119*(6), 866-872.
19. Kraft, S., Buchenauer, L., & Polte, T. (2021). Mold, Mycotoxins and a Dysregulated Immune System: A Combination of Concern? International Journal of Molecular Sciences, *22*(22), 12269.
20. Jankovic, J., & Tan, E. K. (2020). Parkinson's disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry, *91*(8), 795-808.
21. Limousin, P., & Foltynie, T. (2019). Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology, *15*(4), 234-242.
22. Lazarou, C., & Akhtar-Danesh, N. (2020). The interplay between genetics and environmental factors in the pathogenesis of Alzheimer's disease. Frontiers in Aging Neuroscience, *12*, 49.
23. Newport, M. T., VanItallie, T. B., Kashiwaya, Y., King, M. T., & Veech, R. L. (极速5分钟快3. A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease. Alzheimer's & Dementia, *11*(1), 99-103.
24. Smith, A. D., Refsum,极速5分钟快3 H., Bottiglieri, T., Fenech, M., Hooshmand, B., McCaddon, A., ... & Obeid, R. (2018). Homocysteine and dementia: An international consensus statement. Journal of Alzheimer's Disease, *62*(2), 561-570.
25. Slutsky, I., Abumaria, N., Wu, L. J., Huang, C., Zhang, L., Li, B., ... & Liu, G. (2010). Enhancement of learning and memory by极速5分钟快3 elevating brain magnesium. Neuron, *65*(2), 165-177.
26. Dyall, S. C. (2015). Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Frontiers in Aging Neuroscience, *7*, 52.
27. Mancuso, C., & Barone, E. (2019). The heme oxygenase/biliverdin reductase pathway in drug research and development. Current Drug Metabolism, *20*(6), 454-459.
28. Sears, M. E. (2013). Chelation: harnessing and enhancing heavy metal detoxification—a review. The Scientific World Journal, *2013*.
29. Bystad, M., Grønli, O., Rasmussen, I. D., Gundersen, N., Nordvang, L., Wang-Iversen, H., & Aslaksen, P. M. (2016). Transcranial direct current stimulation as a memory enhancer in patients with Alzheimer’s disease: a randomized, placebo-controlled trial. Alzheimer's Research & Therapy, *8*(1), 1-9.
30. Laver, K. E., Lange, B., George, S., Deutsch, J. E., Saposnik, G., & Crot极速5分钟快3ty, M. (2017). Virtual reality for stroke rehabilitation. Cochrane Database of Systematic Reviews, (11).
31. Hamblin, M. R. (2018). Photobiomodulation for Alzheimer’s disease: has the light dawned? Photonics, *6*(3), 77.
32. Landgrave-Gómez, J., Mercado-Gómez, O., & Guevara-Guzmán, R. (2015). Epigenetic mechanisms in neurological and neurodegenerative diseases. Frontiers in Cellular Neuroscience, *9*, 58.
33. Dorsey, E. R., & Topol, E. J. (2016). State of telehealth. New England Journal of Medicine, *375*(2), 154-161.